ArticleKidney international reports2025
Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Response to the Letter to the Editor Entitled "Re-examining the Causal Link Between Immunosuppression Delay and Kidney Outcomes in Autoimmune Membranous Nephropathy".Kidney international reports · 2025Article
- Reexamining the Causal Link Between Immunosuppression Delay and Kidney Outcomes in Autoimmune Membranous Nephropathy.Kidney international reports · 2025Article
- Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite new treatments, kidney dysfunction in autoimmune membranous nephropathy (aMN) remains challenging. Immunosuppression is initiated after "watchful-wait" to avoid side effects in patients who might achieve spontaneous remission; however, the impact of this approach on kidney function is unclear. Methods: This was a retrospective longitudinal cohort study of patients with new consecutive aMN from 2003 to 2019 from 3 UK centers. Patients were assigned to 5 categories, Results: A total of 312 patients were included with 5.0 years median follow-up from diagnosis. A significant association was found between waiting time to immunosuppression and decline in eGFR ( Conclusion: In patients with aMN requiring immunosuppression, delayed treatment leads to worse kidney outcomes. A simple categorization using baseline eGFR and uPCR can help predict spontaneous remission and potential kidney function decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.